The ALK inhibitor PF-06463922 is effective as a single agent in neuroblastoma driven by expression of ALK and MYCN

• Main Authors: J. Guan (Author), E. R. Tucker (Author), H. Wan (Author), D. Chand (Author), L. S. Danielson (Author), K. Ruuth (Author), A. El Wakil (Author), B. Witek (Author), Y. Jamin (Author), G. Umapathy (Author), S. P. Robinson (Author), T. W. Johnson (Author), T. Smeal (Author), T. Martinsson (Author), L. Chesler (Author), R. H. Palmer (Author), B. Hallberg (Author)
• Format: Book
• Published: The Company of Biologists, 2016-09-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

The first-in-class inhibitor of ALK, c-MET and ROS1, crizotinib (Xalkori), has shown remarkable clinical efficacy in treatment of ALK-positive non-small cell lung cancer. However, in neuroblastoma, activating mutations in the ALK kinase domain are typically refractory to crizotinib treatment, highli...